EQ-3
2.8.2016 10:02:00 CEST | Business Wire | Press release
According to the renowned market research company Berg Insight, eQ-3 is the European market leader in smart home for the third time in a row. The company jumps ahead with a market share of 35 percent in installed whole home solutions: About 285,000 households in Europe already use whole home solutions from eQ-3. With regard to smart thermostats, there are over 560,000 households already. In total eQ-3 has shipped more than 18 million wireless home control devices.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160802005208/en/
The market research company Berg Insight confirms the company located in Leer, Germany, as market leader in its fourth edition of the “Smart Homes and Home Automation” study. Whole home systems by eQ-3 are already installed in around 285,000 households in Europe today. These include more than six million devices based on the Homematic product line as well as the next smart home generation Homematic IP and major OEM solutions such as RWE smart home. The company has recorded continuous growth over many years in the smart home area, largely thanks to the product line Homematic introduced almost ten years ago. In the last three years, Homematic growth exceeded 75 percent per year, even with the already large installed base. According to Berg Insight, Homematic has three times more installed whole home systems in the consumer segment than all KNX manufacturers together.
The same positive trend becomes apparent when looking at the smart thermostats sector: Over 560,000 households in Europe use smart thermostats from eQ-3 already today, representing a market share of 41 percent. According to Berg Insight, the heating control system MAX! is used in 320,000 households.
In contrast to other smart thermostat solutions, eQ-3 solutions such as Homematic IP, Homematic, and MAX! provide heating control not only for the entire home, but on a room-by-room basis. Therefore, the energy is controlled based on the actual usage of rooms and associated need for heating rooms individually. This results in significantly increased energy savings. Furthermore, while other solutions typically consist of a boiler switch, a thermostat, and a gateway only, the eQ-3 solutions additionally include radiator thermostats, wall thermostats, and window sensors and other devices. When considering that a typical eQ-3 heating solution has eight to nine versus two to three devices, the European market share of eQ-3 based on the number of individual devices would be even above 70 percent.
Another major difference to other smart heating solutions is that eQ-3 provides a smooth extension path to full smart home solutions today, seamlessly adding security and alarm, light and shade, access control and many other applications for mass consumer deployment. The eQ-3 smart home products are marketed under the Homematic IP, Homematic, and MAX! brands through a wide variety of channels, including specialty retailers, Amazon and many online stores, large CE retailers, DIY, and installers that are served by our own field sales force together with the leading electrical wholesaler Sonepar. Additionally, eQ-3 is the technology and product provider behind smart home offerings from RWE, Deutsche Telekom and many other OEMs. With Homematic IP and an earlier OEM solution, eQ-3 is the pioneer in delivering an all-IPv6 smart home solution. Further strengths of Homematic IP are its ease-of-use, confirmed best-in-class security, and a leading position in data privacy thanks to a free, anonymously operated cloud service.
Homematic IP by eQ-3
About eQ-3:
eQ-3 is one of the leading innovation and technology companies for home control and consumer electronics. With more than 200 different types of products, eQ-3 today provides the largest product portfolio in the industry and has placed more than 18 million wireless solutions in more than 600,000 households on the market. This makes eQ-3 the European market leader in smart home technology based on the number of whole home solutions and electronic radiator thermostats installed. Homematic is the leading smart home platform with more than 80 devices and open communication interfaces. Homematic IP, the next generation of Homematic, is based on the Internet standard IPv6 as open platform and fully compatible with the devices of the Homematic family. The products are designed and developed at the headquarters in Leer, Germany. The final manufacturing takes place in the own production plant in South China. The ELV/eQ-3 group has been family owned since its foundation. The eQ-3 group was founded in 2007 as a spin-off from the ELV Elektronik AG, existing since 1978. Further information: www.eQ-3.de , www.HomeMatic.com , www.homematic-ip.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160802005208/en/
Contact:
Press contact:
Sinje Salamon
eQ-3 AG
Marketing
Manager
+49 (491) 6008 - 626
sinje.salamon@eq-3.de
or
PR
agency:
Benjamin Kolthoff
P.U.N.K.T. Gesellschaft
für Public
Relations mbH
+49 (40) 85 37 60 - 29
bkolthoff@punkt-pr.de
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
